{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:38:48Z","timestamp":1792733928934,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Irritable bowel syndrome (IBS) is a prevalent functional disorder, comprising constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), and mixed (IBS-M) subtypes. Emerging research has shown that the pathophysiological influences of SIBO are significant in IBS, particularly in IBS-D. Variations in therapeutic responsiveness and diagnostic paradigms across IBS subtypes necessitate a tailored, subtype-specific management framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A review of identification strategies, SIBO subtype-specific prevalence, and treatment outcomes was supplemented through controlled randomized trials and observational studies. The treatment outcomes were evaluated in relation to SIBO and within the frameworks of rifaximin, neomycin, probiotics, and dietary modulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The prevalence of SIBO is notably greater in IBS patients, particularly in those with IBS-D, with figures estimating ranges from 30 to 60% depending upon the diagnostic methods and cutoff thresholds. Though limited in its sensitivity and standardization, breath testing, particularly glucose hydrogen\/methane tests, remains the most widely accessible diagnostic technique. Methane-predominant SIBO in IBS-C does respond better to rifaximin\u2013neomycin combinations, but rifaximin provides strong symptom relief in IBS-D. Significant gaps persist, however, with the absence of longitudinal outcome measurements and standardization of IBS diagnostic criteria. In order to improve the care for IBS patients, the strategies targeting precision medicine with microbiota profiling and algorithm-driven personalized therapies must be accorded priority.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SIBO is increasingly recognized as a potential contributor in a subset of patients with IBS, with rifaximin being most beneficial for IBS-D, particularly when utilized in addition to dietary measures. IBS-C and IBS-M require individualized, multimodal therapy, and future studies should direct efforts toward subtype-specific, precision medicine treatments for improved long-term outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11739-026-04418-7","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:02:16Z","timestamp":1781722936000},"page":"2373-2393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted antibiotic and dietary approaches in managing small intestinal bacterial overgrowth across irritable bowel syndrome subtypes"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7919-9594","authenticated-orcid":false,"given":"Yousra","family":"Iftequar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7977-6101","authenticated-orcid":false,"given":"Prakhar","family":"Bajpai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1099-8775","authenticated-orcid":false,"given":"Rajvi","family":"Dav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5580-8804","authenticated-orcid":false,"given":"Kaza Sri","family":"Harshitha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8214-4581","authenticated-orcid":false,"given":"Chandan","family":"C","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3448-7677","authenticated-orcid":false,"given":"Rakshit","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4186-550X","authenticated-orcid":false,"given":"Sneha","family":"Chimkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3075-0684","authenticated-orcid":false,"given":"Rishi","family":"Chowdhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"22","key":"4418_CR1","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.3748\/wjg.v20.i22.6759","volume":"20","author":"L Saha","year":"2014","unstructured":"Saha L (2014) Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol 20(22):6759\u20136773. https:\/\/doi.org\/10.3748\/wjg.v20.i22.6759","journal-title":"World J Gastroenterol"},{"key":"4418_CR2","unstructured":"Nathani RR, Sodhani S, Vadakekut ES. Irritable Bowel Syndrome. [Updated 2025 Sep 15]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534810\/"},{"issue":"2","key":"4418_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000505287","volume":"38","author":"S Grad","year":"2020","unstructured":"Grad S, Dumitrascu DL (2020) Irritable bowel syndrome subtypes: new names for old medical conditions. Dig Dis 38(2):122\u2013127. https:\/\/doi.org\/10.1159\/000505287","journal-title":"Dig Dis"},{"issue":"2","key":"4418_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.5009\/gnl16126","volume":"11","author":"UC Ghoshal","year":"2017","unstructured":"Ghoshal UC, Shukla R, Ghoshal U (2017) Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver 11(2):196\u2013208. https:\/\/doi.org\/10.5009\/gnl16126","journal-title":"Gut Liver"},{"issue":"2","key":"4418_CR5","first-page":"112","volume":"3","author":"AC Dukowicz","year":"2007","unstructured":"Dukowicz AC, Lacy BE, Levine GM (2007) Small intestinal bacterial overgrowth. Gastroenterol Hepatol 3(2):112\u2013122","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"4418_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40348-016-0036-8","volume":"3","author":"BP Chumpitazi","year":"2016","unstructured":"Chumpitazi BP, Shulman RJ (2016) Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome. Mol Cell Pediatr 3(1):11. https:\/\/doi.org\/10.1186\/s40348-016-0036-8","journal-title":"Mol Cell Pediatr"},{"issue":"3","key":"4418_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1053\/j.gastro.2022.04.002","volume":"163","author":"D Bushyhead","year":"2022","unstructured":"Bushyhead D, Quigley EMM (2022) Small intestinal bacterial overgrowth-pathophysiology and its implications for definition and management. Gastroenterology 163(3):593\u2013607. https:\/\/doi.org\/10.1053\/j.gastro.2022.04.002","journal-title":"Gastroenterology"},{"issue":"3","key":"4418_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000336174","volume":"85","author":"SV Rana","year":"2012","unstructured":"Rana SV, Sharma S, Kaur J, Sinha SK, Singh K (2012) Comparison of lactulose and glucose breath test for diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Digestion 85(3):243\u2013247. https:\/\/doi.org\/10.1159\/000336174","journal-title":"Digestion"},{"issue":"3","key":"4418_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.15386\/mpr-2832","volume":"98","author":"T Iacob","year":"2025","unstructured":"Iacob T, Scarlata GGM, Abenavoli L, Leucu\u021ba DC, Lup\u0219e MS, Dumitra\u0219cu DL (2025) Irritable bowel syndrome after Clostridioides difficile infection. Med Pharm Rep 98(3):320\u2013324. https:\/\/doi.org\/10.15386\/mpr-2832","journal-title":"Med Pharm Rep"},{"issue":"3","key":"4418_CR10","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3390\/nu18030490","volume":"18","author":"W Fusco","year":"2026","unstructured":"Fusco W, De Maio F, Porcari S, Severino A, Salvi D, Piccirelli S et al (2026) Informed therapeutic microbiome modulation for post-infectious irritable bowel syndrome: pilot experience of a microbiome clinic. Nutrients 18(3):490. https:\/\/doi.org\/10.3390\/nu18030490","journal-title":"Nutrients"},{"issue":"5","key":"4418_CR11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4764","volume":"11","author":"SH Bin Waqar","year":"2019","unstructured":"Bin Waqar SH, Rehan A (2019) Methane and constipation-predominant irritable bowel syndrome: entwining pillars of emerging neurogastroenterology. Cureus 11(5):e4764. https:\/\/doi.org\/10.7759\/cureus.4764","journal-title":"Cureus"},{"key":"4418_CR12","doi-asserted-by":"publisher","first-page":"1429133","DOI":"10.3389\/fmed.2024.1429133","volume":"11","author":"X Cheng","year":"2024","unstructured":"Cheng X, Ren C, Mei X, Jiang Y, Zhou Y (2024) Gut microbiota and irritable bowel syndrome: status and prospect. Front Med 11:1429133. https:\/\/doi.org\/10.3389\/fmed.2024.1429133","journal-title":"Front Med"},{"issue":"11","key":"4418_CR13","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/apt.13199","volume":"41","author":"J Schwille-Kiuntke","year":"2015","unstructured":"Schwille-Kiuntke J, Mazurak N, Enck P (2015) Systematic review with meta-analysis: post-infectious irritable bowel syndrome after travellers\u2019 diarrhoea. Aliment Pharmacol Ther 41(11):1029\u20131037. https:\/\/doi.org\/10.1111\/apt.13199","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"4418_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/19490976.2016.1218585","volume":"7","author":"H Raskov","year":"2016","unstructured":"Raskov H, Burcharth J, Pommergaard HC, Rosenberg J (2016) Irritable bowel syndrome, the microbiota and the gut-brain axis. Gut microbes 7(5):365\u2013383. https:\/\/doi.org\/10.1080\/19490976.2016.1218585","journal-title":"Gut microbes"},{"issue":"11","key":"4418_CR15","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3389\/fpsyt.2020.00664","volume":"10","author":"W Takakura","year":"2020","unstructured":"Takakura W, Pimentel M (2020) Small intestinal bacterial overgrowth and irritable bowel syndrome\u2014an update. Front Psychiatry 10(11):664. https:\/\/doi.org\/10.3389\/fpsyt.2020.00664","journal-title":"Front Psychiatry"},{"key":"4418_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.14309\/ajg.0000000000000504","volume":"115","author":"A Shah","year":"2020","unstructured":"Shah A, Talley NJ, Jones M, Kendall BJ, Koloski N, Walker MM, Morrison M, Holtmann GJ (2020) Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. Am J Gastroenterol 115:190\u2013201. https:\/\/doi.org\/10.14309\/ajg.0000000000000504","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"4418_CR17","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/ajg.2015.220","volume":"110","author":"T Ringel-Kulka","year":"2015","unstructured":"Ringel-Kulka T, Choi CH, Temas D, Kim A, Maier DM, Scott K, Galanko JA, Ringel Y (2015) Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome. Am J Gastroenterol 110(9):1339\u20131346. https:\/\/doi.org\/10.1038\/ajg.2015.220","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"4418_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14817","volume":"36","author":"P Kashyap","year":"2024","unstructured":"Kashyap P, Moayyedi P, Quigley EMM, Simren M, Vanner S (2024) Critical appraisal of the SIBO hypothesis and breath testing: a clinical practice update endorsed by the European society of neurogastroenterology and motility (ESNM) and the American neurogastroenterology and motility society (ANMS). Neurogastroenterol Motil 36(6):e14817. https:\/\/doi.org\/10.1111\/nmo.14817","journal-title":"Neurogastroenterol Motil"},{"issue":"1","key":"4418_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12876-020-01336-6","volume":"20","author":"X Zhuang","year":"2020","unstructured":"Zhuang X, Tian Z, Luo M, Xiong L (2020) Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol 20(1):187. https:\/\/doi.org\/10.1186\/s12876-020-01336-6","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"4418_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.rgmxen.2024.08.003","volume":"90","author":"C Von Muhlenbrock","year":"2025","unstructured":"Von Muhlenbrock C, Landskron G, Madrid AM (2025) Treatment of small intestinal bacterial overgrowth in Chilean patients with irritable bowel syndrome: A prospective and comparative study. Rev Gastroenterol M\u00e9xico Engl Ed 90(1):54\u201362. https:\/\/doi.org\/10.1016\/j.rgmxen.2024.08.003","journal-title":"Rev Gastroenterol M\u00e9xico Engl Ed"},{"issue":"2","key":"4418_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jgh3.12240","volume":"4","author":"RM Harvie","year":"2020","unstructured":"Harvie RM, Tuck CJ, Schultz M (2020) Evaluation of lactulose, lactose, and fructose breath testing in clinical practice: a focus on methane. JGH Open 4(2):198\u2013205. https:\/\/doi.org\/10.1002\/jgh3.12240","journal-title":"JGH Open"},{"issue":"8","key":"4418_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3760\/cma.j.issn.0578-1426.2017.08.003","volume":"56","author":"H Wei","year":"2017","unstructured":"Wei H, Liu ZJ, Wang K, Zheng W, Duan LP (2017) The dietary features of diarrhea predominant irritable bowel syndrome patients with small intestinal bowel overgrowth. Zhonghua Nei Ke Za Zhi 56(8):567\u2013571. https:\/\/doi.org\/10.3760\/cma.j.issn.0578-1426.2017.08.003","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"2","key":"4418_CR23","first-page":"111","volume":"39","author":"JA Barkin","year":"2019","unstructured":"Barkin JA, Keihanian T, Barkin JS, Antequera CM, Moshiree B (2019) Preferential usage of rifaximin for the treatment of hydrogen-positive small intestinal bacterial overgrowth. Rev Gastroenterol Peru 39(2):111\u2013115 (PMID\u202f: 31333225)","journal-title":"Rev Gastroenterol Peru"},{"issue":"10","key":"4418_CR24","first-page":"1314","volume":"17","author":"E Scarpellini","year":"2013","unstructured":"Scarpellini E, Giorgio V, Gabrielli M, Filoni S, Vitale G, Tortora A, Ojetti V, Gigante G, Fundar\u00f3 C, Gasbarrini A (2013) Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacolog Sci 17(10):1314\u20131320","journal-title":"Eur Rev Med Pharmacolog Sci"},{"issue":"3","key":"4418_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/MEG.0000000000000557","volume":"28","author":"UC Ghoshal","year":"2016","unstructured":"Ghoshal UC, Srivastava D, Misra A, Ghoshal U (2016) A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial. Eur J Gastroenterol Hepatol 28(3):281\u2013289. https:\/\/doi.org\/10.1097\/MEG.0000000000000557","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"4418_CR26","unstructured":"Pimentel M, Morales W, Lezcano S, Sun-Chuan D, Low K, Yang J. Low-Dose Nocturnal Tegaserod or Erythromycin Delays Symptom Recurrence After Treatment of Irritable Bowel Syndrome Based on Presumed Bacterial Overgrowth. Gastroenterol Hepatol. 2009;5(6):435\u2013442. Accessed June 28, 2025. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2886395\/"},{"issue":"3","key":"4418_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.7453\/gahmj.2014.019","volume":"3","author":"V Chedid","year":"2014","unstructured":"Chedid V, Dhalla S, Clarke JO, Roland BC, Dunbar KB, Koh J et al (2014) Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med 3(3):16\u201324. https:\/\/doi.org\/10.7453\/gahmj.2014.019","journal-title":"Glob Adv Health Med"},{"issue":"3","key":"4418_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1517\/13543780902780175","volume":"18","author":"M Pimentel","year":"2009","unstructured":"Pimentel M (2009) Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs 18(3):349\u2013358. https:\/\/doi.org\/10.1517\/13543780902780175","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"4418_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/2040622312472008","volume":"4","author":"M Saadi","year":"2013","unstructured":"Saadi M, McCallum RW (2013) Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use. Ther Adv Chronic Dis 4(2):71\u201375. https:\/\/doi.org\/10.1177\/2040622312472008","journal-title":"Ther Adv Chronic Dis"},{"issue":"10","key":"4418_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202400356","volume":"357","author":"A Deljavan Ghodrati","year":"2024","unstructured":"Deljavan Ghodrati A, Comoglu T (2024) Rifaximin and alternative agents in the management of irritable bowel syndrome: a comprehensive review. Arch Pharm (Weinheim) 357(10):e2400356. https:\/\/doi.org\/10.1002\/ardp.202400356","journal-title":"Arch Pharm (Weinheim)"},{"key":"4418_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104936","volume":"159","author":"Y Li","year":"2020","unstructured":"Li Y, Hong G, Yang M et al (2020) Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome. Pharmacol Res 159:104936. https:\/\/doi.org\/10.1016\/j.phrs.2020.104936","journal-title":"Pharmacol Res"},{"issue":"3","key":"4418_CR32","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jpeds.2009.03.033","volume":"155","author":"E Scarpellini","year":"2009","unstructured":"Scarpellini E, Giorgio V, Gabrielli M, Lauritano EC, Pantanella A, Fundar\u00f2 C et al (2009) Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. J Pediatr 155(3):416\u2013420. https:\/\/doi.org\/10.1016\/j.jpeds.2009.03.033","journal-title":"J Pediatr"},{"issue":"1","key":"4418_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.rgmxen.2021.11.013","volume":"88","author":"MG Aja-Cadena","year":"2023","unstructured":"Aja-Cadena MG, Amieva-Balmori M, Taboada-Liceaga HA, Cobos-Quevedo OJ, Hern\u00e1ndez-Ram\u00edrez GA, Reyes-Huerta J, Roesch-Dietlen F, Meixuerio-Daza A, Remes-Troche JM (2023) Prevalence of methanogens and associated factors in patients with irritable bowel syndrome and healthy controls in a Southeastern Mexican population. Revista de Gastroenterolog\u00eda de M\u00e9xico (English Edition) 88(1):50\u201356. https:\/\/doi.org\/10.1016\/j.rgmxen.2021.11.013","journal-title":"Revista de Gastroenterolog\u00eda de M\u00e9xico (English Edition)"},{"issue":"1","key":"4418_CR34","doi-asserted-by":"publisher","first-page":"1933313","DOI":"10.1080\/19490976.2021.1933313","volume":"13","author":"A Gandhi","year":"2021","unstructured":"Gandhi A, Shah A, Jones MP et al (2021) Methane positive small intestinal bacterial overgrowth in inflammatory bowel disease and irritable bowel syndrome: a systematic review and meta-analysis. Gut Microbes 13(1):1933313. https:\/\/doi.org\/10.1080\/19490976.2021.1933313","journal-title":"Gut Microbes"},{"issue":"1","key":"4418_CR35","doi-asserted-by":"publisher","first-page":"2020067","DOI":"10.1080\/19490976.2021.2020067","volume":"14","author":"P Singh","year":"2021","unstructured":"Singh P, Alm EJ, Kelley JM et al (2021) Effect of antibiotic pretreatment on bacterial engraftment after fecal microbiota transplant (FMT) in IBS-D. Gut Microbes 14(1):2020067. https:\/\/doi.org\/10.1080\/19490976.2021.2020067","journal-title":"Gut Microbes"},{"issue":"1","key":"4418_CR36","first-page":"89","volume":"52","author":"L Cuoco","year":"2006","unstructured":"Cuoco L, Salvagnini M (2006) Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol 52(1):89\u201395","journal-title":"Minerva Gastroenterol Dietol"},{"issue":"7","key":"4418_CR37","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3390\/nu17071251","volume":"17","author":"AR Li\u00e9bana-Castillo","year":"2025","unstructured":"Li\u00e9bana-Castillo AR, Redondo-Cuevas L, Nicol\u00e1s \u00c1 et al (2025) Should we treat SIBO patients? impact on quality of life and response to comprehensive treatment: a real-world clinical practice study. Nutrients 17(7):1251. https:\/\/doi.org\/10.3390\/nu17071251","journal-title":"Nutrients"},{"issue":"36","key":"4418_CR38","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.3748\/wjg.v23.i36.6593","volume":"23","author":"E Sinagra","year":"2017","unstructured":"Sinagra E, Morreale GC, Mohammadian G, Fusco G, Guarnotta V, Tomasello G et al (2017) New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol 23(36):6593","journal-title":"World J Gastroenterol"},{"issue":"16","key":"4418_CR39","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.3390\/nu14163382","volume":"14","author":"JP Wielgosz-Grochowska","year":"2022","unstructured":"Wielgosz-Grochowska JP, Domanski N, Drywie\u0144 ME (2022) Efficacy of an irritable bowel syndrome diet in the treatment of small intestinal bacterial overgrowth: a narrative review. Nutrients 14(16):3382. https:\/\/doi.org\/10.3390\/nu14163382","journal-title":"Nutrients"},{"key":"4418_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102208","volume":"64","author":"JR Biesiekierski","year":"2022","unstructured":"Biesiekierski JR, Tuck CJ (2022) Low FODMAP diet beyond IBS: Evidence for use in other conditions. Curr Opin Pharmacol 64:102208","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"4418_CR41","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s10620-024-08767-1","volume":"70","author":"MF Garc\u00eda-Cedillo","year":"2025","unstructured":"Garc\u00eda-Cedillo MF, Villegas-Garc\u00eda FU, Arenas-Martinez JS et al (2025) Rifaximin-alpha increases lactase activity in patients with irritable bowel syndrome without constipation and small intestinal bacterial overgrowth. Dig Dis Sci 70(1):360\u2013366. https:\/\/doi.org\/10.1007\/s10620-024-08767-1","journal-title":"Dig Dis Sci"},{"issue":"3","key":"4418_CR42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/MCG.0b013e31823712b1","volume":"46","author":"B Ki Cha","year":"2012","unstructured":"Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H et al (2012) The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, Double-blind. Placebo-controlled Trial J Clini Gastroenterol 46(3):220\u2013227. https:\/\/doi.org\/10.1097\/MCG.0b013e31823712b1","journal-title":"Placebo-controlled Trial J Clini Gastroenterol"},{"issue":"2","key":"4418_CR43","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s12602-018-9401-3","volume":"11","author":"K Leventogiannis","year":"2019","unstructured":"Leventogiannis K, Gkolfakis P, Spithakis G, Tsatali A, Pistiki A, Sioulas A et al (2019) Effect of a preparation of four probiotics on symptoms of patients with irritable bowel syndrome: association with intestinal bacterial overgrowth. Probiotics Antimicro Prot 11(2):627\u2013634. https:\/\/doi.org\/10.1007\/s12602-018-9401-3","journal-title":"Probiotics Antimicro Prot"},{"issue":"6","key":"4418_CR44","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/MCG.0b013e31820ca4d6","volume":"45","author":"T Ringel-Kulka","year":"2011","unstructured":"Ringel-Kulka T, Palsson OS, Maier D, Carroll I, Galanko JA, Leyer G et al (2011) Probiotic bacteria lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol 45(6):518\u2013525. https:\/\/doi.org\/10.1097\/MCG.0b013e31820ca4d6","journal-title":"J Clin Gastroenterol"},{"issue":"10","key":"4418_CR45","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.3390\/ijms21103531","volume":"21","author":"G Losurdo","year":"2020","unstructured":"Losurdo G, D\u2019Abramo FS, Indellicati G, Lillo C, Ierardi E, Di Leo A (2020) The influence of small intestinal bacterial overgrowth in digestive and extra-intestinal disorders. Int J Mol Sci 21(10):3531. https:\/\/doi.org\/10.3390\/ijms21103531","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4418_CR46","first-page":"3752","volume":"25","author":"T Larussa","year":"2021","unstructured":"Larussa T, Abenavoli L, Corea A, Procopio AC, Giubilei L, Vallelunga R et al (2021) Trends and characteristics associated with dietary triggers and psychological distress in patients with irritable bowel syndrome: a cross-sectional study. Eur Rev Med Pharmacol Sci 25(10):3752\u20133761","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"4418_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/8791916","volume":"2018","author":"SH Lee","year":"2018","unstructured":"Lee SH, Joo NS, Kim KM, Kim KN (2018) The therapeutic effect of a multistrain probiotic on diarrhea-predominant irritable bowel syndrome: a pilot study. Gastroenterol Res Pract 2018:1\u20138. https:\/\/doi.org\/10.1155\/2018\/8791916","journal-title":"Gastroenterol Res Pract"},{"issue":"1","key":"4418_CR48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1004409","volume":"364","author":"M Pimentel","year":"2011","unstructured":"Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J et al (2011) Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364(1):22\u201332","journal-title":"N Engl J Med"},{"issue":"1","key":"4418_CR49","doi-asserted-by":"publisher","first-page":"18140","DOI":"10.1038\/s41598-024-69162-4","volume":"14","author":"G Leite","year":"2024","unstructured":"Leite G, Rezaie A, Morales W, Weitsman S, de Freitas GJ, Barlow GM et al (2024) Low dose rifaximin combined with N-acetylcysteine is superior to rifaximin alone in a rat model of IBS-D: a randomized trial. Sci Rep 14(1):18140","journal-title":"Sci Rep"},{"issue":"3\u20134","key":"4418_CR50","first-page":"143","volume":"51","author":"IG Moraru","year":"2013","unstructured":"Moraru IG, Portincasa P, Moraru AG, Diculescu M, Dumitra\u015fcu DL (2013) Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study. Rom J Intern Med 51(3\u20134):143\u2013147","journal-title":"Rom J Intern Med"},{"issue":"5","key":"4418_CR51","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1159\/000528954","volume":"41","author":"LM Bustos Fern\u00e1ndez","year":"2023","unstructured":"Bustos Fern\u00e1ndez LM, Man F, Lasa JS (2023) Impact of saccharomyces boulardii CNCM I-745 on bacterial overgrowth and composition of intestinal microbiota in diarrhea-predominant irritable bowel syndrome patients: results of a randomized pilot study. Dig Dis 41(5):798\u2013809. https:\/\/doi.org\/10.1159\/000528954","journal-title":"Dig Dis"},{"issue":"1","key":"4418_CR52","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.rgmxen.2021.11.013","volume":"88","author":"MG Aja-Cadena","year":"2023","unstructured":"Aja-Cadena MG, Amieva-Balmori M, Taboada-Liceaga HA, Cobos-Quevedo OJ, Hern\u00e1ndez-Ram\u00edrez GA, Reyes-Huerta J et al (2023) Prevalence of methanogens and associated factors in patients with irritable bowel syndrome and healthy controls in a Southeastern Mexican population. Revista de Gastroenterolog\u00eda de M\u00e9xico (English Edition) 88(1):50\u201356. https:\/\/doi.org\/10.1016\/j.rgmxen.2021.11.013","journal-title":"Revista de Gastroenterolog\u00eda de M\u00e9xico (English Edition)"},{"issue":"11","key":"4418_CR53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/jcm6110099","volume":"6","author":"B Lacy","year":"2017","unstructured":"Lacy B, Patel N (2017) Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med 6(11):99. https:\/\/doi.org\/10.3390\/jcm6110099","journal-title":"J Clin Med"},{"issue":"10","key":"4418_CR54","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.3748\/wjg.v20.i10.2482","volume":"20","author":"UC Ghoshal","year":"2014","unstructured":"Ghoshal UC (2014) Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World J Gastroenterol 20(10):2482. https:\/\/doi.org\/10.3748\/wjg.v20.i10.2482","journal-title":"World J Gastroenterol"},{"key":"4418_CR55","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S89999","author":"S Soldi","year":"2015","unstructured":"Soldi S, Vasileiadis S, Uggeri F, Campanale MC, Morelli L, Calanni F et al (2015) Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol. https:\/\/doi.org\/10.2147\/CEG.S89999","journal-title":"Clin Exp Gastroenterol"},{"key":"4418_CR56","doi-asserted-by":"publisher","DOI":"10.17235\/reed.2015.3979\/2015","author":"C Kibune Nagasako","year":"2015","unstructured":"Kibune Nagasako C, Garcia Montes C, Silva Lorena SL, Mesquita MA (2015) Irritable bowel syndrome subtypes clinical and psychological features, body mass index and comorbidities. J Rev Esp Enferm Dig. https:\/\/doi.org\/10.17235\/reed.2015.3979\/2015","journal-title":"J Rev Esp Enferm Dig"},{"issue":"8","key":"4418_CR57","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/MCG.0b013e3181c64c90","volume":"44","author":"K Low","year":"2010","unstructured":"Low K, Hwang L, Hua J, Zhu A, Morales W, Pimentel M (2010) A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol 44(8):547\u2013550. https:\/\/doi.org\/10.1097\/MCG.0b013e3181c64c90","journal-title":"J Clin Gastroenterol"},{"issue":"25","key":"4418_CR58","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.3748\/wjg.v23.i25.4632","volume":"23","author":"RM Harvie","year":"2017","unstructured":"Harvie RM, Chisholm AW, Bisanz JE, Burton JP, Herbison P, Schultz K, Schultz M (2017) Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs. World J Gastroenterol 23(25):4632. https:\/\/doi.org\/10.3748\/wjg.v23.i25.4632","journal-title":"World J Gastroenterol"},{"issue":"2","key":"4418_CR59","doi-asserted-by":"publisher","first-page":"220","DOI":"10.15386\/cjmed-589","volume":"89","author":"A Chira","year":"2016","unstructured":"Chira A, Filip M, Dumitra\u015fcu DL (2016) Patterns of alternation in irritable bowel syndrome. Med Pharm Rep 89(2):220\u2013223. https:\/\/doi.org\/10.15386\/cjmed-589","journal-title":"Med Pharm Rep"},{"key":"4418_CR60","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44807","author":"Z Khan","year":"2023","unstructured":"Khan Z, Khan SK, Reyaz I, Anam H, Ijaz O, Attique I et al (2023) Effectiveness of Rifaximin on the outcomes of irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Cureus. https:\/\/doi.org\/10.7759\/cureus.44807","journal-title":"Cureus"},{"issue":"5","key":"4418_CR61","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.13928","volume":"45","author":"L Gatta","year":"2017","unstructured":"Gatta L, Scarpignato C (2017) Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 45(5):604\u2013616. https:\/\/doi.org\/10.1111\/apt.13928","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"4418_CR62","doi-asserted-by":"publisher","first-page":"557","DOI":"10.7326\/0003-4819-145-8-200610170-00004","volume":"145","author":"M Pimentel","year":"2006","unstructured":"Pimentel M, Park S, Mirocha J, Kane SV, Kong Y (2006) The effect of a nonabsorbed oral antibiotic (Rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145(8):557\u2013563. https:\/\/doi.org\/10.7326\/0003-4819-145-8-200610170-00004","journal-title":"Ann Intern Med"},{"issue":"10","key":"4418_CR63","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000078","volume":"10","author":"SSC Rao","year":"2019","unstructured":"Rao SSC, Bhagatwala J (2019) Small intestinal bacterial overgrowth: clinical features and therapeutic management. Clin Transl Gastroenterol 10(10):e00078. https:\/\/doi.org\/10.14309\/ctg.0000000000000078","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"4418_CR64","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.gtc.2017.09.008","volume":"47","author":"A Adike","year":"2018","unstructured":"Adike A, DiBaise JK (2018) Small intestinal bacterial overgrowth. Gastroenterol Clin North Am 47(1):193\u2013208. https:\/\/doi.org\/10.1016\/j.gtc.2017.09.008","journal-title":"Gastroenterol Clin North Am"},{"issue":"4","key":"4418_CR65","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1053\/j.gastro.2020.06.090","volume":"159","author":"EMM Quigley","year":"2020","unstructured":"Quigley EMM, Murray JA, Pimentel M (2020) AGA clinical practice update on small intestinal bacterial overgrowth: expert review. Gastroenterology 159(4):1526\u20131532. https:\/\/doi.org\/10.1053\/j.gastro.2020.06.090","journal-title":"Gastroenterology"},{"issue":"8","key":"4418_CR66","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41575-019-0171-5","volume":"16","author":"EMM Quigley","year":"2019","unstructured":"Quigley EMM (2019) Symptoms and the small intestinal microbiome \u2014 the unknown explored. Nat Rev Gastroenterol Hepatol 16(8):457\u2013458. https:\/\/doi.org\/10.1038\/s41575-019-0171-5","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"4418_CR67","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/MEG.0000000000000122","volume":"26","author":"UC Ghoshal","year":"2014","unstructured":"Ghoshal UC, Srivastava D, Ghoshal U, Misra A (2014) Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. Eur J Gastroenterol Hepatol 26(7):753\u2013760. https:\/\/doi.org\/10.1097\/MEG.0000000000000122","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"4418_CR68","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1023\/A:1021738515885","volume":"48","author":"M Pimentel","year":"2003","unstructured":"Pimentel M, Mayer AG, Park S, Chow EJ, Hasan A, Kong Y (2003) Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci 48(1):86\u201392. https:\/\/doi.org\/10.1023\/A:1021738515885","journal-title":"Dig Dis Sci"},{"issue":"7","key":"4418_CR69","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.3390\/jcm12072558","volume":"12","author":"SD Shaikh","year":"2023","unstructured":"Shaikh SD, Sun N, Canakis A, Park WY, Weber HC (2023) Irritable bowel syndrome and the gut microbiome: a comprehensive review. JCM 12(7):2558. https:\/\/doi.org\/10.3390\/jcm12072558","journal-title":"JCM"},{"key":"4418_CR70","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S67231","author":"R Schey","year":"2015","unstructured":"Schey R, Iorio N, Malik Z (2015) Profile of rifaximin and its potential in the treatment of irritable bowel syndrome. Clin Exp Gastroenterol. https:\/\/doi.org\/10.2147\/CEG.S67231","journal-title":"Clin Exp Gastroenterol"},{"issue":"1","key":"4418_CR71","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.rgmx.2018.02.008","volume":"84","author":"MJ Schmulson","year":"2019","unstructured":"Schmulson MJ, Frati-Munari AC (2019) S\u00edntomas intestinales en pacientes que reciben inhibidores de bomba de protones (IBP). Resultados de una encuesta multic\u00e9ntrica en M\u00e9xico. Rev Gastroenterol Mex 84(1):44\u201351. https:\/\/doi.org\/10.1016\/j.rgmx.2018.02.008","journal-title":"Rev Gastroenterol Mex"},{"issue":"5","key":"4418_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2016.32","volume":"7","author":"A Acosta","year":"2016","unstructured":"Acosta A, Camilleri M, Shin A, Nord SL, O\u2019Neill J, Gray AV et al (2016) Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome. Clin Transl Gastroenterol 7(5):e173. https:\/\/doi.org\/10.1038\/ctg.2016.32","journal-title":"Clin Transl Gastroenterol"},{"key":"4418_CR73","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3389\/fmicb.2018.01600","volume":"9","author":"X Zhuang","year":"2018","unstructured":"Zhuang X, Tian Z, Li L, Zeng Z, Chen M, Xiong L (2018) Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome. Front Microbiol 9:1600. https:\/\/doi.org\/10.3389\/fmicb.2018.01600","journal-title":"Front Microbiol"},{"issue":"3","key":"4418_CR74","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s10620-018-5344-5","volume":"64","author":"AK Tuteja","year":"2019","unstructured":"Tuteja AK, Talley NJ, Stoddard GJ, Verne GN (2019) Double-blind placebo-controlled study of rifaximin and lactulose hydrogen breath test in gulf war veterans with irritable bowel syndrome. Dig Dis Sci 64(3):838\u2013845. https:\/\/doi.org\/10.1007\/s10620-018-5344-5","journal-title":"Dig Dis Sci"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04418-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04418-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04418-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:02:06Z","timestamp":1792731726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04418-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4418"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04418-7","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors certify that they have NO affiliations with or involvement in any organization or entity with any financial interest. The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional IRB approval was not taken as this is a review article.","order":2,"name":"Ethics","label":"Ethical approval\/IRB Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We have employed a Large Language Model (ChatGPT, OpenAI, Claude) to refine the English language and improve readability. This process focused solely on improving the text's clarity and style, without generating or adding any new information to the content.","order":4,"name":"Ethics","label":"Large language model (LLM)\u2014generative AI use statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a narrative review of previously published literature and does not containany studies involving human participants or animals performed by any of the authors.","order":5,"name":"Ethics","label":"Human and animal rights","group":{"name":"EthicsHeading","label":"Declarations"}}]}}